At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia
In Brief
A Phase 3 clinical trial evaluating Enlicitide, Ezetimibe, and 4 other interventions for Hypercholesterolemia. Completed, enrolled 301 participants across 35 sites in 8 countries.
Detailed Summary
The main purpose of this study is to assess whether enlicitide is superior to ezetimibe or bempedoic acid or ezetimibe + bempedoic acid in reducing low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia, and to evaluate its safety and tolerability. The primary study hypotheses are enlicitide is superior to ezetimibe, bempedoic acid, and ezetimibe + bempedoic acid on mean percent change from baseline in LDL-C at week 8.
Study Details
Timeline
Interventions
Oral tablet
Oral tablet
Oral capsule
enlicitide-matching placebo oral tablet
ezetimibe-matching placebo oral tablet
bempedoic acid-matching placebo oral capsule